CDP-choline is studied as a source of choline and in neurological outcomes. A positive memory-task finding does not establish broad neuroprotection.
Citicoline participates in choline-related metabolism. Research spans healthy older adults with memory complaints and people with neurological disease. These populations, endpoints and treatment contexts must remain separate. Radiolabel disposition is not a parent-drug elimination curve.
Memory-task and stroke-recovery findings differ. This draft does not assign a general cognition or neuroprotection score.
Assessment belongs to each claim and outcome. An article’s editorial status is not a grade of a substance’s safety or efficacy.Measurements after administration support conversion to choline and cytidine; the parent compound and its metabolites require separate interpretation. [4]
Descriptions of experience in their reported context. Direction does not imply benefit, and these observations do not define a universal intensity score.
Not assessed. No sourced subjective observations have been curated for this article.
What the research measured, for whom, and under which exposure. Findings remain attached to the study’s task or clinical endpoint.
A secondary episodic-memory endpoint improved relative to placebo. Clinical importance and generalizability remain uncertain. [1]
ICTUS found no significant recovery advantage over placebo and was stopped for futility. [2]
Published exposure records, distinguished by source category. These describe study or reference context and are not personal dosing recommendations.
500 mg [1]
Selected population and study formulation; not evidence for benefit in all ages.
Absorption, metabolism and elimination depend on the analyte, route, formulation, physiology and other exposures.
Available tracer disposition includes metabolites and tissue pathways; no parent-citicoline half-life is assigned. [3]
Measured analyte: Unchanged citicoline. Route: Oral. Formulation: Radiolabeled study compound. Population: Healthy adult volunteers.
Measured radioactivity follows parent-derived material, not specifically unchanged citicoline; no decay model is justified.
Read the source context ↗Not establishedNo numeric estimate [3]
Measured radioactivity follows parent-derived material, not specifically unchanged citicoline; no decay model is justified.
Adverse effects, interactions, tolerance and withdrawal in the cited contexts. This section is not an exhaustive interaction checker.
The source, the finding and its limitations. Funding information is reported where curated; an unassessed disclosure does not mean a study had no commercial funding.
Found improvement in secondary episodic and composite memory endpoints.
Limitations Selected older population, short follow-up and secondary endpoints; not a broad cognitive-enhancement result.
Funding / disclosures Ingredient-supplier involvement is reported; full funding disclosures require editorial review.
Did not demonstrate a recovery advantage in moderate-to-severe acute ischemic stroke.
Limitations A clinical stroke population and hospital treatment sequence; findings do not resolve healthy-memory questions.
Funding / disclosures Ferrer Grupo.
Tracked absorption and elimination of radiolabeled material through multiple pathways.
Limitations Small study; radioactivity includes metabolites and cannot define a parent-drug half-life.
Funding / disclosures Not assessed in this draft.
Distinguished unchanged compound from circulating choline and cytidine.
Limitations Mechanistic disposition findings do not demonstrate cognitive efficacy.
Funding / disclosures Not assessed in this draft.
Source of the displayed formula, molecular weight, structure and connectivity SMILES.
Limitations The parent compound identity is distinct from salts, formulations and commercial product quality.
Funding / disclosures US National Library of Medicine.
Each relationship retains its participants, roles and context. Shared membership does not imply that substances should be combined.
Human and animal metabolism experiments distinguished parent compound from metabolites
Limitation Metabolite availability alone does not establish a memory benefit.
Evidence strength: not formally assessed.
Not assessed. Absence of a legal record is not a statement of legal status.
This article is a sourced draft. Editorial review has not been recorded. Content date: Sep 29, 2026.